Hana Pharm Co., Ltd.(KR:293480)
â‚©8,080.00-10.00 (-0.12%)
KR:293480
Hana Pharm Co., Ltd. financials statements
â‚©8,080.00
At close:-10.00 (-0.12%)
Want to see KR:293480 full AI Analyst Report?
Hana Pharm Co., Ltd. (293480) Ratios
Hana Pharm Co., Ltd. Ratios
KR:293480's free cash flow for Q2 2026 was ₩-9.74B. For the 2026 fiscal year, KR:293480's free cash flow was decreased by ₩-16.65B and operating cash flow was ₩6.91B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.84 | 3.33 | 1.82 | 2.32 | 3.44 |
| Quick Ratio | 0.93 | 1.84 | 0.96 | 1.39 | 2.44 |
| Cash Ratio | 0.15 | 0.27 | 0.03 | 0.28 | 0.16 |
| Solvency Ratio | 0.19 | 0.40 | 0.43 | 0.40 | 0.65 |
| Operating Cash Flow Ratio | 0.14 | 0.79 | 0.33 | 0.69 | 0.63 |
| Short-Term Operating Cash Flow Coverage | 0.27 | 7.23 | 0.79 | 2.96 | 3.06 |
| Net Current Asset Value | â‚© 13.08B | â‚© 33.16B | â‚© 32.02B | â‚© 25.96B | â‚© 88.86B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.14 | 0.08 | 0.08 | 0.10 | 0.04 |
| Debt-to-Equity Ratio | 0.19 | 0.09 | 0.10 | 0.13 | 0.04 |
| Debt-to-Capital Ratio | 0.16 | 0.09 | 0.09 | 0.11 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.07 | 0.01 | 0.07 | 0.00 |
| Financial Leverage Ratio | 1.33 | 1.24 | 1.25 | 1.29 | 1.20 |
| Debt Service Coverage Ratio | 0.82 | 8.21 | 1.24 | 2.84 | 4.01 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 53.22 | 796.89 |
| Debt to Market Cap | 0.28 | 0.14 | 0.10 | 0.10 | 0.02 |
| Interest Debt Per Share | 3303.87 | 1683.76 | 1533.79 | 2005.05 | 648.52 |
| Net Debt to EBITDA | 1.32 | 0.63 | 0.72 | 0.57 | 0.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.12% | 62.70% | 62.19% | 62.24% | 66.61% |
| EBIT Margin | 10.82% | 11.16% | 12.04% | 14.85% | 18.27% |
| EBITDA Margin | 15.43% | 14.59% | 15.45% | 17.90% | 21.21% |
| Operating Profit Margin | 10.82% | 11.16% | 12.04% | 14.78% | 18.33% |
| Pretax Profit Margin | 7.67% | 11.27% | 12.43% | 14.57% | 18.25% |
| Net Profit Margin | 3.67% | 9.43% | 9.95% | 11.53% | 14.26% |
| Continuous Operations Profit Margin | 3.67% | 9.43% | 9.95% | 11.53% | 14.26% |
| Net Income Per EBT | 47.76% | 83.68% | 80.03% | 79.13% | 78.15% |
| EBT Per EBIT | 70.91% | 100.95% | 103.24% | 98.55% | 99.55% |
| Return on Assets (ROA) | 2.10% | 5.56% | 6.41% | 7.03% | 9.23% |
| Return on Equity (ROE) | 2.80% | 6.87% | 8.03% | 9.06% | 11.12% |
| Return on Capital Employed (ROCE) | 7.32% | 7.18% | 9.25% | 10.35% | 13.71% |
| Return on Invested Capital (ROIC) | 3.20% | 5.93% | 6.82% | 7.87% | 10.34% |
| Return on Tangible Assets | 2.19% | 5.80% | 6.69% | 7.28% | 9.64% |
| Earnings Yield | 4.40% | 11.27% | 8.98% | 7.89% | 8.33% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.22 | 5.21 | 4.86 | 4.76 | 4.59 |
| Payables Turnover | 13.79 | 12.63 | 13.16 | 9.87 | 9.82 |
| Inventory Turnover | 1.60 | 1.77 | 1.76 | 1.92 | 1.61 |
| Fixed Asset Turnover | 1.15 | 1.21 | 1.42 | 1.39 | 1.60 |
| Asset Turnover | 0.57 | 0.59 | 0.64 | 0.61 | 0.65 |
| Working Capital Turnover Ratio | 3.75 | 3.74 | 4.27 | 2.66 | 1.84 |
| Cash Conversion Cycle | 271.12 | 247.15 | 255.27 | 229.57 | 268.79 |
| Days of Sales Outstanding | 69.96 | 70.06 | 75.07 | 76.70 | 79.50 |
| Days of Inventory Outstanding | 227.62 | 206.00 | 207.92 | 189.84 | 226.45 |
| Days of Payables Outstanding | 26.46 | 28.91 | 27.73 | 36.97 | 37.16 |
| Operating Cycle | 297.58 | 276.06 | 283.00 | 266.54 | 305.96 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 516.30 | 1462.42 | 1063.86 | 1785.28 | 1537.70 |
| Free Cash Flow Per Share | -1118.06 | 698.91 | 215.06 | -282.56 | -548.73 |
| Dividend Paid and CapEx Coverage Ratio | 0.24 | 1.15 | 0.78 | 0.69 | 0.60 |
| Capital Expenditure Coverage Ratio | 0.32 | 1.92 | 1.25 | 0.86 | 0.74 |
| Operating Cash Flow Coverage Ratio | 0.16 | 0.87 | 0.69 | 0.91 | 2.38 |
| Operating Cash Flow to Sales Ratio | 0.04 | 0.11 | 0.08 | 0.15 | 0.13 |
| Free Cash Flow Yield | -9.96% | 6.41% | 1.50% | -1.59% | -2.72% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 22.13 | 8.86 | 11.14 | 12.67 | 12.00 |
| Price-to-Sales (P/S) Ratio | 0.83 | 0.84 | 1.11 | 1.46 | 1.71 |
| Price-to-Book (P/B) Ratio | 0.64 | 0.61 | 0.89 | 1.15 | 1.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.04 | 15.60 | 66.87 | -63.00 | -36.72 |
| Price-to-Operating Cash Flow Ratio | 21.73 | 7.45 | 13.52 | 9.97 | 13.10 |
| Price-to-Earnings Growth (PEG) Ratio | -0.38 | -1.89 | -1.37 | -0.78 | 0.13 |
| Enterprise Value Multiple | 6.72 | 6.36 | 7.90 | 8.73 | 8.17 |
| Enterprise Value | 248.29B | 209.17B | 273.87B | 329.47B | 340.34B |
| EV to EBITDA | 6.72 | 6.36 | 7.90 | 8.73 | 8.17 |
| EV to Sales | 1.04 | 0.93 | 1.22 | 1.56 | 1.73 |
| EV to Free Cash Flow | -12.50 | 17.30 | 73.61 | -67.41 | -37.18 |
| EV to Operating Cash Flow | 27.06 | 8.27 | 14.88 | 10.67 | 13.27 |
| Tangible Book Value Per Share | 16621.38 | 16961.96 | 15236.88 | 14822.06 | 14328.92 |
| Shareholders’ Equity Per Share | 17633.98 | 17872.49 | 16069.42 | 15515.17 | 15098.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.52 | 0.16 | 0.20 | 0.21 | 0.22 |
| Revenue Per Share | 13475.74 | 13026.18 | 12975.13 | 12188.28 | 11772.15 |
| Net Income Per Share | 493.90 | 1228.40 | 1290.99 | 1405.12 | 1679.08 |
| Tax Burden | 0.48 | 0.84 | 0.80 | 0.79 | 0.78 |
| Interest Burden | 0.71 | 1.01 | 1.03 | 0.98 | 1.00 |
| Research & Development to Revenue | 0.06 | 0.04 | 0.03 | 0.02 | 0.02 |
| SG&A to Revenue | 0.24 | 0.25 | 0.25 | 0.23 | 0.21 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.05 | 1.19 | 0.82 | 1.27 | 0.92 |
Currency in KRW

